Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 24, 2024

BUY
$2.14 - $11.62 $96,300 - $522,899
45,000 New
45,000 $534,000
Q4 2021

Feb 02, 2022

SELL
$8.69 - $12.48 $434,500 - $624,000
-50,000 Closed
0 $0
Q3 2021

Oct 22, 2021

BUY
$8.43 - $16.81 $421,500 - $840,499
50,000 New
50,000 $626,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $315M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.